Trifluoperazine-d8

Trifluoperazine-d8

• UNSPSC Description: Trifluoperazine-d8 is a deuterium labeled Trifluoperazine. Trifluoperazine is an antipsychotic phenothiazine agent and a selective α1-adrenergic receptor antagonist. Trifluoperazine is also a potent dopamine D2 receptor inhibitor [1][2].
• Target Antigen: Adrenergic Receptor; Autophagy; Dopamine Receptor; Influenza Virus; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Anti-infection;Autophagy;GPCR/G Protein;Neuronal Signaling;Others
• Applications: COVID-19-anti-virus
• Field of Research: Cancer; Neurological Disease
• Solubility: 10 mM in DMSO
• Smiles: FC(C(C=C1N2CCCN3C([2H])([2H])C([2H])([2H])N(C)C([2H])([2H])C3([2H])[2H])=CC=C1SC4=C2C=CC=C4)(F)F
• Molecular Weight: 415.54
• References & Citations: [1]Huerta-Bahena J, et al. Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects. Mol Pharmacol. 1983 Jan;23(1):67-70.|[2]Marques LO, et al. Trifluoperazine for schizophrenia. Cochrane Database Syst Rev. 2004;(1):CD003545.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported